Dr. Adey started out in biotechnology development at the University of Texas where he researched alternative applications of microarrays in the lab of Andrew D. Ellington, Ph.D. He later served as interim director of the UT microarray core facility and then helped set up the UT genome sequencing and analysis facility in the early days of next generation sequencing. He then completed his doctoral studies in the Molecular and Cellular Biology Program at the University of Washington in the lab of Jay Shendure, M.D., Ph.D. in the Genome Sciences Department.
Previous research highlights include pioneering a novel transposase-based method for rapid, low-input DNA sequencing library construction, which I extended to the genome-wide analysis of DNA methylation. I also applied long-range sequencing methods to produce the first haplotype resolved genome and epigenome of an aneuploid cell line, HeLa, where I investigated the role of haplotype and copy number on the epigenetic and transcriptional landscape. I plan to continue my focus on the development and implementation of novel strategies to investigate the epigenome with high precision. This includes single cell approaches to disambiguate epigenetic and transcriptional heterogeneity within populations of cells which is typically obscured by bulk preparation methods. This work will provide insight into the dynamic regulatory landscape of cells and may reveal functional and targetable subpopulations in the context of disease intervention.
Evan Eichler, Ph.D., is a Professor and Howard Hughes Medical Institute Investigator in the Department of Genome Sciences, University of Washington School of Medicine. He graduated with a B.Sc. Honours degree in Biology from the University of Saskatchewan, Canada, in 1990. He received his Ph.D. in 1995 from the Department of Molecular and Human Genetics at Baylor College of Medicine, Houston, Texas. After a Hollaender postdoctoral fellowship at Lawrence Livermore National Laboratory, he joined the faculty of Case Western Reserve University in 1997 and later the University of Washington in 2004. He was a March of Dimes Basil O’Connor Scholar (1998–2001), appointed as an HHMI Investigator (2005), awarded an AAAS Fellowship (2006) and the American Society of Human Genetics Curt Stern Award (2008), and elected to the National Academy of Sciences (2012) and the National Academy of Medicine (2017). He is an editor of Genome Research and has served on various scientific advisory boards for both NIH and NSF. His research group provided the first genome-wide view of segmental duplications within human and other primate genomes and he is a leader in an effort to identify and sequence normal and disease-causing structural variation in the human genome. The long-term goal of his research is to understand the evolution and mechanisms of recent gene duplication and its relationship to copy number variation and human disease.
Gosia Trynka strongly believes that interdisciplinary approaches are essential to achieve meaningful insights into biological processes. The combination of molecular techniques, genomic assays, and computational methods that we develop and apply to study the immune system is a reflection of my own career path through several disciplines within biology and genetics.
With a backround in molecular biology, Gosia became interested in medical and population genetic approaches to study genetic determinants for immune related diseases. Gosia joined Prof. Cisca Wijmenga’s group where Gosia was a co-lead analyst for the genome-wide association study (GWAS) and an Immunochip study for coeliac disease (an immune disease of the small intestine resulting from intolerance to gluten). These studies resulted in identification of tens of disease risk loci and pointed to strong shared genetic backround between celiac disease and a range of other common immune conditions, including type-1 diabetes, rheumatoid arthritis, and inflammatory bowel disease.
Despite the great success in mapping disease risk variants, Gosia was disappointed by the limited insights that we gained in understanding biology of complex immune diseases. Gosia therefore carried out my postdoctoral research at Brigham and Women’s Hospital, Harvard Medical School and Broad Institute where she joined Dr. Soumya Raychaudhuri’s and Dr. Robert Plenge’s groups. Gosia invested my time in developing statistical methods that allow translation of GWAS associations into biological functions. By integrating disease-associated variants with functional genomics data, these approaches pointed to specific cell types being relevant in the pathogenesis of numerous complex traits, including immune diseases. Gosia ‘s group at the Sanger Institute continuous with experimental and computational efforts to further map and translate immune disease genetic variants to function.
Dr. Law received her Bachelor’s degree in Biochemistry and Biophysics from Oregon State University in 2001 and her Ph.D. degree in Biochemistry from the Johns Hopkins University School of Medicine in 2006 where she investigated RNA editing in Trypanosome brucei in the Sollner-Webb laboratory. Dr. Law’s post-doctoral research in the laboratory of Dr. Steven E. Jacobsen at the University of California, Los Angeles focused on understanding the roles of small RNAs in targeting DNA methylation and gene silencing in Arabidopsis thaliana and was supported by a Ruth L. Kirschstein National Research Service Award from the National Institute of Health. In September of 2012, Dr. Law joined the Plant Biology program at the Salk Institute for Biological Sciences as an Assistant Professor where she continues to focus on epigenetics and other chromatin-based processes. In 2015, Dr. Law received the Hearst Foundation Developmental chair and was named a Rita Allen Foundation Scholar and in 2018 Dr. Law was selected as a Newsweek “Women of the Future” Nominee.